These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1616229)

  • 1. Alpha-interferon-induced nodular rheumatoid arthritis in renal cell carcinoma.
    Ueno Y; Sohma T
    Ann Intern Med; 1992 Aug; 117(3):266-7. PubMed ID: 1616229
    [No Abstract]   [Full Text] [Related]  

  • 2. Recombinant interferon-alpha 2 antibodies in renal cell carcinoma. Delta-P Study Group.
    Prümmer O; Porzsolt F
    J Interferon Res; 1994 Aug; 14(4):193-5. PubMed ID: 7822873
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe hyponatremia caused by hyperglycaemia due to interferon alpha therapy in advanced renal cell carcinoma.
    Soetekouw PM; Koopman M; Burger D; Tjan-Heijnen VC; De Mulder PH
    Acta Oncol; 2009; 48(1):154-6. PubMed ID: 19101828
    [No Abstract]   [Full Text] [Related]  

  • 4. Interferon alfa-2a tretinoin in patients with metastatic renal cell carcinoma: a pilot study.
    Paule B; Bonhomme-Faivre L; Rudant E; Ferrière F
    Am J Health Syst Pharm; 1997 Jan; 54(2):190-2. PubMed ID: 9117809
    [No Abstract]   [Full Text] [Related]  

  • 5. Two injections of interferon-alpha could trigger the development of rheumatoid arthritis.
    Funauchi M; Ohno M; Nozaki Y; Kinoshita K; Sugiyama M; Kanamaru A
    Clin Exp Rheumatol; 2002; 20(6):871. PubMed ID: 12508785
    [No Abstract]   [Full Text] [Related]  

  • 6. Immune thrombocytopenia during interferon-alfa therapy for renal cell carcinoma.
    Akamatsu S; Asazuma A; Kanamaru S; Takenawa J; Soeda A
    Hinyokika Kiyo; 2006 Oct; 52(10):789-92. PubMed ID: 17131869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
    Fiorentino B; Di Stefano P; Giuliani C; Amatetti C; Tinari N; Natoli C; Garufi C; Iacobelli S
    Br J Cancer; 1992 Nov; 66(5):981-3. PubMed ID: 1419647
    [No Abstract]   [Full Text] [Related]  

  • 8. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma.
    Nathan PD; Gore ME; Eisen TG
    J Clin Oncol; 2002 Mar; 20(5):1429-30. PubMed ID: 11870194
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon alfa-2b.
    Vermeulen PB; Dirix LY; Martin M; Lemmens J; Van Oosterom AT
    J Natl Cancer Inst; 1997 Sep; 89(17):1316-7. PubMed ID: 9293925
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma. A randomized trial.
    Steineck G; Strander H; Carbin BE; Borgström E; Wallin L; Achtnich U; Arvidsson A; Söderlund V; Näslund I; Esposti PL
    Acta Oncol; 1990; 29(2):155-62. PubMed ID: 2185803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent diagnosis of hairy cell leukemia and renal cell carcinoma.
    Undar B; Demirkan F; Oztop I; Ozcan MA; Ozsan GH
    Leuk Lymphoma; 2001 Jul; 42(3):567-8. PubMed ID: 11699427
    [No Abstract]   [Full Text] [Related]  

  • 12. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Vieweg J
    Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
    [No Abstract]   [Full Text] [Related]  

  • 13. Roferon-A in solid tumor therapy.
    Semin Oncol; 1989 Feb; 16(1 Suppl 1):1-50. PubMed ID: 2919287
    [No Abstract]   [Full Text] [Related]  

  • 14. Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate--a phase II study.
    Fosså SD; Gunderson R; Moe B
    Cancer; 1990 Jun; 65(11):2451-4. PubMed ID: 2337859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of renal cell carcinoma with daily low-dose alpha-interferon.
    Marshall ME; Simpson W; Butler K; Fried A; Fer M
    J Biol Response Mod; 1989 Oct; 8(5):453-61. PubMed ID: 2795090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lichenoid Dermatitis From Interferon alpha-2a in a Patient With Metastatic Renal Cell Carcinoma and Seronegative HCV.
    Bush AE; Hymes SR; Silapunt S
    J Drugs Dermatol; 2017 Jul; 16(7):714-716. PubMed ID: 28697228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon update.
    Pyrhönen S
    Urologe A; 2004 Sep; 43 Suppl 3():S137-8. PubMed ID: 15148576
    [No Abstract]   [Full Text] [Related]  

  • 18. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma.
    Johnson DM; Hayat SQ; Burton GV
    J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440
    [No Abstract]   [Full Text] [Related]  

  • 19. Cell sensitivity to reaferon in patients with renal cell cancer after reaferon therapy.
    Shkapova EA; Kurtasova LM; Savchenko AA
    Bull Exp Biol Med; 2007 Jul; 144(1):80-2. PubMed ID: 18256759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alfa therapy against metastatic iris tumor of renal cell carcinoma.
    Ikeda T; Sato K; Tokuyama T
    Arch Ophthalmol; 2000 Jun; 118(6):846-7. PubMed ID: 10865325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.